New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
09:00 EDTRTRXRetrophin falls 8.1%
Retrophin is down 8.1%, or 96c, to $10.85
News For RTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 15, 2015
09:38 EDTRTRXRetrophin management to meet with Deutsche Bank
Subscribe for More Information
January 14, 2015
07:18 EDTRTRXRetrophin management to meet with Deutsche Bank
Subscribe for More Information
January 13, 2015
07:16 EDTRTRXRetrophin management to meet with Deutsche Bank
Subscribe for More Information
January 12, 2015
08:08 EDTRTRXRetrophin aquires exclusive right to purchase cholic acid from Asklepion
Retrophin and Asklepion Pharmaceuticals, LLC, a privately held rare disease pharmaceutical development company, today announced the signing of a definitive agreement under which Retrophin has acquired the exclusive right to purchase from Asklepion, all worldwide rights, titles, and ownership of cholic acid for the treatment of bile acid synthesis defects, if approved by the U.S. FDA. Under the terms of the agreement, Retrophin will pay Asklepion an upfront payment of $5M and up to $73M in milestones based on approval and net product sales, plus tiered royalties on future net sales of cholic acid. Retrophin has secured a line of credit from current lenders to cover necessary payments. Cholic acid is being considered for approval in a late-stage review by the FDA and is currently approved in Europe for the treatment of inborn errors in primary bile acid synthesis. It restores endogenous bile acid pool levels while inhibiting abnormal bile acid synthesis. The clinical use of cholic acid has been documented in medical literature for several single enzyme bile acid synthesis defects since the mid-1990s.
07:17 EDTRTRXRetrophin management to meet with Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use